Searle & CO. Sells 18,628 Shares of Pfizer Inc. (NYSE:PFE)

Searle & CO. decreased its holdings in Pfizer Inc. (NYSE:PFE) by 16.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 93,069 shares of the biopharmaceutical company’s stock after selling 18,628 shares during the quarter. Searle & CO.’s holdings in Pfizer were worth $2,693,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Guidance Capital Inc. increased its position in shares of Pfizer by 2.1% during the third quarter. Guidance Capital Inc. now owns 34,886 shares of the biopharmaceutical company’s stock valued at $1,019,000 after buying an additional 706 shares during the period. Greenleaf Trust grew its holdings in shares of Pfizer by 4.2% during the 3rd quarter. Greenleaf Trust now owns 297,265 shares of the biopharmaceutical company’s stock worth $8,603,000 after acquiring an additional 11,935 shares during the period. Commerzbank Aktiengesellschaft FI raised its holdings in Pfizer by 16.1% in the third quarter. Commerzbank Aktiengesellschaft FI now owns 397,385 shares of the biopharmaceutical company’s stock worth $11,500,000 after purchasing an additional 55,024 shares in the last quarter. Plan Group Financial LLC boosted its holdings in shares of Pfizer by 11.7% during the 3rd quarter. Plan Group Financial LLC now owns 31,317 shares of the biopharmaceutical company’s stock valued at $906,000 after buying an additional 3,289 shares in the last quarter. Finally, Elevated Capital Advisors LLC grew its position in shares of Pfizer by 6.7% in the 3rd quarter. Elevated Capital Advisors LLC now owns 23,198 shares of the biopharmaceutical company’s stock worth $671,000 after buying an additional 1,460 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 0.5 %

Shares of NYSE PFE traded down $0.13 during mid-day trading on Wednesday, reaching $28.71. 8,641,572 shares of the company were exchanged, compared to its average volume of 36,861,973. The stock has a market cap of $162.69 billion, a price-to-earnings ratio of -481.33, a P/E/G ratio of 1.02 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a 50-day moving average of $29.07 and a 200 day moving average of $28.48. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the prior year, the business posted $0.67 EPS. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. On average, research analysts expect that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.85%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Analyst Ratings Changes

A number of analysts have recently commented on the company. UBS Group boosted their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Sanford C. Bernstein began coverage on shares of Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.91.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.